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(vs. warfarin), and apixaban (vs. aspirin) to be cost-effective; data on
clopidogrelaspirin (vs. aspirin) to be conflicting, and genotyped-warfarin and xi-
melagtran not cost-effective. CONCLUSIONS: Cost-effectiveness models of pharma-
cologic SPAF have been extensively published; but none have estimated the comparative
cost-effectiveness of newer agents. Models used similar structures and non-drug-specific
inputs, and commonly find innovator strategies to be cost-effective.
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OBJECTIVES: To undertake an economic evaluation of rivaroxaban relative to the
local standard of care, acenocoumarol, for stroke prevention in atrial fibrillation
(AF) patients with one or more risk factors.METHODS:A Markov model designed to
reflect the natural progression of AF patients through different health states was
developed and adapted to the Greek setting. The analysis was undertaken from a
payer perspective. Baseline event rates (adjusted to three month cycles) and rela-
tive treatment effects (RRs) were derived from the safety on treatment analysis of
the ROCKET AF study. Utility values for events were based on literature. A treat-
ment-related disutility of 0.05 was applied to acenocoumarol arm. Costs assigned
to each health state reflect local drug acquisition, monitoring, event management
and transportation costs and reflect the year 2012. An incremental cost effective-
ness ratio (ICER) per quality-adjusted-life year (QALY) gained was calculated. One-
way sensitivity analyses were conducted to identify key model drivers. Probabilis-
tic analysis was undertaken to deal with uncertainty. The horizon of analysis was
over patient life time and both cost and outcomes were discounted at 3.5%.
RESULTS: The average total cost of rivaroxaban-treated patients was €985 higher
compared to acenocoumarol. Rivaroxaban was associated with additional drug
acquisition costs (€5,275), however these were mainly offset by reduced monitoring
(€3,947) and event costs (€343). Moreover, rivaroxaban was associated with a 0.22
increment in QALYs leading to an ICER of €4,517/QALY gained. Sensitivity analyses
showed that the cost-effectiveness results are fairly robust with discontinuation
rate of rivaroxaban, acenocoumarol monitoring visits, acenocoumarol-related util-
ity decrement, RR for rivaroxaban versus acenocoumarol for stroke having the
highest impact on results. Probabilistic analysis revealed a high probability of ri-
varoxaban being cost-effective at a threshold of €30,000 or €40,000/QALY.
CONCLUSIONS: Rivaroxaban may represent a cost-effective option for the preven-
tion of stroke in AF patients with one or more risk factors.
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OBJECTIVES: In the PLATO study, ticagrelor significantly reduced the rate of myo-
cardial infarction (MI), stroke, or death from vascular causes without a significant
increase in the rate of overall major bleeding compared to Clopidogrel in the man-
agement of acute coronary syndrome (ACS) patients. We aimed to assess the long
term cost-effectiveness of ticagrelor versus clopidogrel in the management of ACS
patients in Hong Kong. METHODS: A Markov decision analytic model was used to
perform a cost-effectiveness analysis (CEA) of treating ACS patients for one year
with ticagrelor plus aspirin (group 1) compared with clopidogrel plus aspirin (group
2) from the Hong Kong health care provider perspective. The model simulates a
cohort of 45-year-old patients with ACS moving between different health status in
each Markov cycle of 1 year. The time horizon was lifetime (85 years old). Health
states included patient in ACS without event, myocardial infarction (MI), and death
from vascular cause. Outcome measures included lifetime costs, quality-adjusted
life years (QALYs) gained and incremental cost-effectiveness ratios (ICERs). Event
rates of group 1 are adopted from the PLATO study and rates of group 2 from the
Prince of Wales Hospital ACS Registry in Hong Kong. Probabilistic sensitivity anal-
yses using Monte Carlo simulations were conducted to assess parameter
uncertainty. RESULTS: The ICER for ticagrelor compared to clopidogrel in the treat-
ment of ACS was HK$34,441 (US$4,415) per QALY gained. For the subset of patients
with ST elevation myocardial infarction (STEMI) and non-ST elevation ACS
(NSTEACS), the ICERs per QALY gained were HK$ 33,402 (US$4,282) and HK$ 38,844
(4,980) respectively. Ticagrelor treatment strategy was cost-effective over 99% of
the Monte Carlo simulation using a cost-effectiveness threshold of 3 times gross
domestic product (GDP) per capita in Hong Kong. CONCLUSIONS: The treatment of
ACS patients with ticagrelor for 12 months is considered cost-effective compared
with clopidogrel from a health care provider perspective.
PCV51
COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF STROKE
AND SYSTEMIC EMBOLISM IN ADULT PATIENTS WITH NON-VALVULAR
ATRIAL FIBRILLATION WITH ONE OR MORE RISK FACTORS – A UK PERSPECTIVE
Asukai Y1, Duran A1, Lloyd A1, McLeod EJ1, Evers T2, Broughton J3
1IMS Health, London, UK, 2Bayer HealthCare AG, Wuppertal, Germany, 3Bayer Plc, Newbury, UK
OBJECTIVES: To evaluate the cost-effectiveness of the once daily oral anticoagu-
lant rivaroxaban for prevention of stroke and systemic embolism in non-valvular
atrial fibrillation (NVAF) patients from a UK payer perspective. METHODS: A
Markov model was developed to evaluate cost-effectiveness over a lifetime time
horizon. Costs and benefits were discounted at 3.5%. The patient population of
interest were AF patients with one or more risk factors currently treated with
warfarin. Clinical inputs were supplied from Safety-on-Treatment data from the
Phase III ROCKET trial or informed by systematically reviewed literature. The In-
tention-to-Treat (ITT) dataset was also used in a sensitivity analysis. Warfarin
efficacy data was adjusted to be reflective of the level of INR control found in
Western Europe and baseline risk was adjusted to be reflective of the UK popula-
tion. Economic inputs were based on unit costs from the BNF, PSSRU and NHS
Reference costs and resource use was from a dedicated observational study. Utility
inputs were taken from a systematic review and included baseline utilities for AF,
disutilities for clinical events and warfarin treatment. RESULTS: Base case analysis
versus warfarin resulted in a total per patient incremental cost of £705 and an
incremental QALY gain of 0.2459 with an estimated ICER of £2,869. The ITT analysis
returned an ICER of £3,404, with an incremental cost of £775 and an incremental
QALY of 0.2277. The sensitivity analyses found that the biggest drivers of the result
were discontinuation rates, warfarin monitoring cost in primary care, warfarin
disutility and frequency of warfarin monitoring. The PSA indicates that the prob-
ability of rivaroxaban being cost-effective at a willingness-to-pay threshold of
£20,000 is 97%. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to war-
farin in the prevention of stroke and systemic embolism in NVAF patients with one
or more risk factors as evaluated from a UK payer perspective.
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OBJECTIVES: Statin monotherapy is the mainstay of LDL-C management for CHD
patients in Portugal, however several therapeutic options are available and pre-
dicted to have different clinical and economical impact. This analysis estimates the
Cost-Effectiveness (CE) of adding ezetimibe 10 mg (EZ10) to generic atorvastatin
10/20 mg (A10/20) against generic atorvastatin titration (A20/40) and against switch
to rosuvastatin 10/20 mg (R10/20) in Portuguese CHD patients who are currently
above LDL-C goal (2.5mmol/L). METHODS: The analysis was based on a previ-
ously published Markov model, employed to evaluate the life-time costs and health
outcomes, including life-years (LY) and quality adjusted life-years (QALY). The
model incorporated Framingham risk equations, Portuguese population character-
istics, CHD event rates, quality of life estimates, local resource use and due unit
costs. RESULTS: From 18 CHD patient risk profiles, discounted lifetime costs per
patient with A20/40, R10/20 and A10/20EZ10 treatment were €20,987, €23,134 and
€25,476, respectively. Average gain with A10/20EZ10 were 0.43 LY and 0.17 QALY
versus A20/40; and 0.38 LY and 0.15 QALY versus R10/20. Thus, the incremental
costs per QALY gained by switching patients from A10/20 to A20/40EZ10 were
€26,435 and €15,907 against titrating to A20/40 and switch to R10/20, respectively.
Based on the Portuguese CE acceptability frontier with a willingness-to-pay value
of €30.000/QALY gained, A10/20EZ10 is projected to be CE for CHD patients on
secondary prevention. CONCLUSIONS: In the Portuguese CHD patients not at
LDL-C goal treated with A10/20, adding EZ10 is CE when compared with atorvasta-
tin titration or switching to rosuvastatin. Moreover, the expected erosion of atorv-
astatin generics’ price will favor CE ratio of A10/20EZ10 versus R10/20 switch.
Thus, ezetimibe is effective in lowering LDL-C, and based on the analysis con-
ducted, is projected to reduce CV events, improve quality of life, and is cost-effec-
tive by commonly used criteria in Portugal.
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OBJECTIVES: Recently, the first single pill (SPC) triple-combination antihyperten-
sive therapy with valsartan(VAL), amlodipine(AML) and hydrochlorothiazide(H-
CTZ) has been available. The aim of this study is to compare the cost-utility of
single pill triple combination with each of the dual combinations deriving from the
same components in patients with moderate to severe hypertension. This is the
first study to evaluate the CUA of this SPC. METHODS: A Markov model with eight
health states was constructed. The short-term effect of antihypertensive treat-
ment on blood pressure was extrapolated through the Hellenic SCORE and
Framingham risk equations in order to estimate the long-term survival and qual-
ity-adjusted life-years (QALYs). Pharmaceutical cost was extracted from the official
price bulletins. Cost of adverse events was derived from international literature,
reflecting €2012. Outcomes and costs were evaluated over lifetime, divided into
annual cycles and were discounted at 3.0%. The analysis was conducted from a
Greek third-party-payer perspective. RESULTS: The cost of treatment with triple
combination was estimated at €17,499 in comparison to €18,203 for AML/VAL,
€16,069 for VAL/HCTZ and €11,945 for AML/HCTZ. The QALYs of the triple combi-
nation were 12.76 vs. 12.64, 12.61 and 12.38 of double combinations respectively,
resulting in incremental QALYs gained of triple vs. double combination in 0.12, 0.15
and 0.38 respectively. The incremental cost-effectiveness ratio (ICER) per QALY
gained with the triple combination versus VAL/HCTZ and AML/HCTZ was far lower
than the Greek GDP per capita (9,649€, 14,581€, respectively), while the triple com-
bination was found to be dominant in comparison with AML/VAL. Extensive sen-
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